

# Bellevue AI Health – The future-proof healthcare investment solution



Investment Company with Variable Capital (SICAV) according to Luxembourg Laws – UCITS  
Marketing document – for private investors: AT, CH, DE, ES, LU, GB

## We are witnessing another major technology turning point

The release of ChatGPT introduced the general public to the power of generative artificial intelligence (GenAI). GenAI matches and to some extent exceeds human capabilities and can create novel professional-quality content in a wide range of formats – text, speech, images, audio, video, or code. An easy-to-use tool with an impressive range of capabilities, GenAI makes quick and precise analysis and utilization of huge pools of data practicable, which, in turn, is creating completely new possibilities in various industries. The healthcare sector is viewed as a major beneficiary of GenAI.

### Why invest?

The various large sources of data that already exist in healthcare systems can be used to spur the deployment of GenAI. These big data sets were amassed over several decades and they now serve as a foundational cornerstone for so-called deep learning applications. Such developments will add tremendous momentum to the ongoing process of digital transformation in the healthcare system.

We strongly believe that companies that are methodically investing in GenAI will gain a decisive and sustainable competitive advantage over the competition.

### Key areas of GenAI in healthcare

#### More efficient administrative processes

Doctors and nurses spend as much as 25% of their working hours on administrative tasks that have no direct benefit for the patient. GenAI can dramatically reduce the burden of healthcare administration.

#### Faster and more targeted drug development activities

GenAI is also being deployed more frequently in R&D. It can speed up the drug discovery and design process and improve the success rate of clinical trials.

#### Better treatment quality

By using GenAI, diseases can be diagnosed earlier, more accurately and more quickly, and treatment modalities that have been used for years can be made even better.

Clinical added value

### In a nutshell

- Healthcare systems will benefit from the huge pools of data that have been built up over decades
- Early adopters of GenAI will have a lasting competitive advantage
- GenAI will be a relevant driver of shareholder value
- Sweet spot: Well-capitalized companies with strong AI capabilities







### Fund facts

Investment manager	Bellevue Asset Management AG
Launch date	End of November 2023
Benchmark	MSCI World Healthcare
ISIN B-USD Mgt. Fee	LU2721086093 1.60%
ISIN B-EUR Mgt. Fee	LU2721086416 1.60%
Legal entity	Luxembourg UCITS V SICAV
Custodian	CACEIS Investor Services Bank S.A., Luxembourg

## Bellevue AI Health: Attractive return potential with a defensive risk profile

The Bellevue AI Health Fund is a global equity fund with an actively managed portfolio of 50 to 70 stocks, mostly from the healthcare sector, rounded out with a small number of tech companies that have considerable exposure to the healthcare industry. Its focus is on liquid mega and large caps, with a modest allocation to mid cap stocks. In addition to fundamental aspects ranging from valuation and growth profiles to profitability, a proprietary «AI Affinity Score» is used to determine how attractive a company is from an AI perspective.

Investment candidates are companies that:

-  are integrating AI into their business strategy
-  have made AI a board-level issue
-  are allocating a significant amount of capital and human resources to AI
-  are using AI to optimize and automate internal business processes
-  are using AI to better understand their customers
-  are deploying AI to develop new products and services

### Opportunities

- GenAI is speeding up the process of digitization and automation across the healthcare system.
- GenAI can enhance patient care, simplify processes and procedures, and lead to better decisions.
- Companies that use or provide GenAI tools for healthcare-relevant purposes will gain a sustainable competitive advantage.
- Shareholder value creation will largely be determined by a company's AI strategy and its execution.
- Bellevue – a pioneer in healthcare investing since 1993 and now one of the largest independent investors in the healthcare space in Europe.

### Risks

- The fund invests in equities. Stocks are subject to price fluctuations, so there is a risk of falling prices.
- The investments the fund makes may be denominated in foreign currency, which can entail a foreign-exchange risk relative to the fund's base currency.
- The fund may invest some of its assets in financial instruments that may have relatively low levels of liquidity under certain circumstances, which may then affect the liquidity of the fund's own shares.
- There are additional risks in the form of political and social unrest when investing in emerging markets.
- The fund may use derivatives. Derivatives offer greater upside potential yet also carry greater downside risk.

## Management Team



**Stefan Blum**  
Portfolio Manager  
since inception of the fund



**Marcel Fritsch**  
Portfolio Manager  
since inception of the fund

## Bellevue – the specialist for healthcare investing since 1993

As one of the largest and most experienced healthcare investors with more than 20 healthcare experts, we focus on high-conviction special themes within the healthcare sector. We offer well-diversified investment strategies focused on the healthcare subsectors of medical technology and healthcare services, digital health, and biotechnology, as well as on regional and thematic investment strategies.

### Contact

Bellevue Asset Management AG  
Seestrasse 16, CH-8700 Küsnacht  
T +41 44 267 67 00  
[www.bellevue.ch](http://www.bellevue.ch), [info@bellevue.ch](mailto:info@bellevue.ch)

## Disclaimer

This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. It is particularly not intended for US persons, as defined under Regulation S of the U.S. Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as recommendation or investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. For more information about the associated costs, please refer to the related costs and fees section of the prospectus. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of the subfund. The performance of a benchmark shall not be indicative of past or future performance of the subfund. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and half-yearly reports. Please take note of the risk factors. Countries of distribution and local representatives. This subfund of Bellevue Funds (Lux) SICAV is registered and admitted for public distribution in AT, DE, LU, ES, SG (res.) and CH, for Hong Kong the subfund has been notified to the Luxembourg Regulator. Austria, Germany: Paying and information agent: Zeidler Legal Process Outsourcing Limited, 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland; E-Mail: [facilities\\_agent@zeidlerlegaliservices.com](mailto:facilities_agent@zeidlerlegaliservices.com) and CACEIS Investor Services Bank S.A., 14, Porte de France, L-4360 Esch-sur-Alzette, Luxembourg. Spain: Representative: Atl Capital, Calle de Montalbán 9, ES-28014 Madrid - CNMV under the number 938 Switzerland: The Bellevue Funds (Lux) SICAV is registered for public offering and distribution in Switzerland with the Swiss Financial Market Supervisory Authority, Representative agent in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zürich. You can obtain the sales prospectus, Key Information Document ("PRIIP - KID"), statutes and the current annual and half-yearly reports, the current share prices and further information about the fund free of charge in German from the management company Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, the representative agent in Switzerland or online at [www.bellevue.ch](http://www.bellevue.ch). In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the representative agent. The Summary of Investor Rights is available under: [https://www.waystone.com/wp-content/uploads/2021/08/Waystone\\_Management\\_Company\\_Lux\\_SA\\_Summary\\_of\\_Investor\\_Rights\\_-\\_August\\_2021.pdf](https://www.waystone.com/wp-content/uploads/2021/08/Waystone_Management_Company_Lux_SA_Summary_of_Investor_Rights_-_August_2021.pdf). The management company may decide to withdraw the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU. Copyright © 2023 Bellevue Asset Management, Inc. All rights reserved. Citywire information is proprietary and confidential to Citywire Financial Publishers Ltd ("Citywire"), may not be copied and Citywire excludes any liability arising out of its use. © 2023 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. The most important terms are explained in the glossary at [www.bellevue.ch/en/glossary](http://www.bellevue.ch/en/glossary).